MARK S. FRANKEL, Ph.D.
Director
Program on Scientific Freedom, Responsibility and Law
American Association for the Advancement of Science

Mark S. Frankel is director of the AAAS Scientific Freedom, Responsibility and Law Program, where he develops and manages the Association's activities related to professional ethics, science and society, and science and law. He is staff officer for the AAAS Committee on Scientific Freedom and Responsibility and the AAAS-American Bar Association National Conference of Lawyers and Scientists, and editor of the quarterly publication, Professional Ethics Report. Before joining AAAS, Dr. Frankel was Director of the Center for the Study of Ethics in the Professions at the Illinois Institute of Technology in Chicago, IL, 1980-86.

Dr. Frankel is on the Board of Directors of the National Patient Safety Foundation and was a AAAS Fellow. He serves on the editorial boards of several professional journals and is the author or editor of 15 AAAS monographs. He is currently directing AAAS projects related to the use of scientific and technical information in the courts, the development of educational materials on the science and ethics of advances in behavioral genetics, and the ethical issues associated with Internet research involving human subjects.

HOWARD W. HUGHES, VMD
Former Chairman
Americans for Medical Progress

Dr. Hughes is Past Chairman of Americans for Medical Progress and currently serves as President of the Scientists Center for Animal Welfare. He recently retired from GlaxoSmithKline where he was Vice President of Laboratory Animal Science worldwide for over 16 years. Prior to going to GSK, he was a Professor of Laboratory Animal Medicine at Penn State University's School of Medicine. He continued his academic affiliations at both PSU and the University of Pennsylvania while at GSK. Dr. Hughes has over 200 publications and presentations as well as six patents to his credit, primarily in the field of cardiac electrophysiology and animal facility design. He is in the forefront of advocates for properly regulated research with animals as an essential component of biomedical research.

PAUL G. ROGERS
Co-Sponsor, 1971 National Cancer Act
Chair, Research!America

Paul G. Rogers is Chair of the Board of Research!America. Mr. Rogers, former US Congressman from Florida (1955-79), served as Chairman of the House Subcommittee on Health and the Environment from 1971-79 before joining Hogan & Hartson. Mr. Rogers sponsored or played a major role in enacting major health and environmental legislation such as: the National Cancer Act of 1971 and 1977; the Medical Device Amendments of 1976; the Health Maintenance Organization Act; the Health Manpower Training Act; the Research on Aging Act; the Comprehensive Drug Abuse Prevention and Control Act of 1970; the Emergency Medical Service Act; the Medicare-Medicaid Anti-Fraud and Abuse Amendments of 1977; the Clean Air Act; the Safe Drinking Water Act; and the Radiation Control for Health & Safety Act. In addition, Mr. Rogers subcommittee exercised oversight of the National Institutes of Health, the Food and Drug Administration, and the Environmental Protection Agency.

At Hogan & Hartson, Mr. Rogers represents a cross-section of health and environmental clients, including corporations, associations and individuals. He lectures widely on health issues and health policy and serves on many national committees. He has received a number of awards including: National Academy of Science Public Welfare Medal (1982); National Health Lawyers Association Health Policy Award (1991); National Cancer Institute "Year 2000" Award; Albert Lasker Award for Public Service (1993); 1994 American Pharmaceutical Association Hugo H. Schaefer Award; 1994 AlliedSignal Achievement Award in Aging; 1994 Distinguished Leadership Award from the University of Florida Health Sciences Center; and the 1995 NOF Leadership Award.

BRIAN J. DRUKER, M.D.
Director, The Leukemia Center
Oregon Health & Science University

Dr. Brian J. Druker is the Director of the Leukemia Center at Oregon Health & Science University (OHSU). As a Professor of Medicine, he has joint appointments in the Department of Cell and Developmental Biology and the Department of Biochemistry and Molecular Biology.

Upon graduating from UC San Diego Medical School in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital: Washington School of Medicine in St. Louis, Missouri. He then trained in Oncology at Harvard's Dana-Farber Cancer Institute.

After he finished his clinical training, Dr. Druker returned to the lab to begin a research career. He studied the regulation of the growth of cancer cells and began to apply this knowledge to cancer therapies. His work has been instrumental in the development of a drug that has shown remarkable success in the treatment of patients with chronic myeloid leukemia. The clinical trials with STI571, commonly known as Gleevec, have been heralded as a new paradigm in cancer therapy. His role in the development of STI571 and application in the clinic have resulted in
numerous awards for Dr. Druker, including the AACR Richard and Hinda Rosenthal Award, the John J. Kenney Award from the Leukemia and Lymphoma Society and the Warren Alpert Prize from Harvard Medical School.

SAMUEL E. BRODER, M.D.
Executive Vice President for Medical Affairs
Celera Genomics

Dr. Samuel Broder was appointed by President Reagan to serve as Director of the National Cancer Institute in 1989, a position he held for six years. His laboratory interests include anti-retroviral therapy, and also, the relationship between immunodeficiency disorders and cancer. His laboratory was instrumental in developing several of the first drugs now widely used in the therapy of AIDS and its related disorders, including Retrovir® (AZT), Videx®(ddI), and HIVID®(ddC). He also oversaw the development of other agents, such as TAXOL®. He has also overseen several drugs in development, including an ultra-low molecular weight glycosaminoglycan for asthma and an orally bioavailable form of paclitaxel. He is the author or co-author of over 320 scientific publications. He has received numerous scientific awards related to his research in cancer and AIDS. He is currently the Executive Vice President for Medical Affairs at Celera Genomics, which recently sequenced and assembled the human and mouse genomes. His current interests relate to applying knowledge of the human genome, comparative genomics, and proteomics to the development of new diagnostics and therapeutics.

OTIS W. BRAWLEY, M.D.
Professor of Medicine and Oncology
Emory University School of Medicine

Otis W. Brawley is Professor of Medicine, Hematology and Oncology at the Emory University School of Medicine and Professor of Epidemiology at the Emory Rollins School of Public Health. He also serves as Associate Director of the Winship Cancer Institute at Emory University and as Director of the Georgia Cancer Coalition Center of Excellence at Grady Hospital.

From 1995 to April 2001, he served as Assistant Director of the National Cancer Institute for the Office of Special Populations Research. Dr. Brawley was previously a Senior Investigator in the Division of Cancer Prevention and Control at the National Cancer Institute where he was one of a group instrumental in the development and launching of the Prostate Cancer Prevention Trial. This 18,000-man trial is looking at screening and epidemiologic issues in prostate cancer as well as the potential for prevention of benign prostatic hyperplasia and prostate cancer. He also served as Chief of the NCI intramural prostate cancer clinic from 1993-1995.

Dr. Brawley's research interests include the screening, epidemiology, diagnosis, prevention and treatment of prostate cancer. He has additional interests in the design of clinical trials, inclusion of minorities in trials and the availability of state-of-the-art health care to the socioeconomically disadvantaged. His work concerning racial differences in patterns of medical care and the similar outcomes among racial and ethnic groups when there is equal treatment is widely cited in medical and lay literature. He is the recipient of numerous awards and was recently named a Georgia Cancer Coalition Eminent Scholar.

Dr. Brawley is board certified in internal medicine and medical oncology. He graduated from college and medical school at the University of Chicago and was an internal medicine resident at University Hospitals of Cleveland at Case Western Reserve University. He trained in Medical Oncology at the National Cancer Institute.

ELLEN STOVALL
President & CEO
National Coalition for Cancer Survivorship

Ellen Stovall, a 29-year survivor of two bouts with cancer, is President & CEO of the National Coalition for Cancer Survivorship (NCCS). NCCS is the nation's only patient-led advocacy organization representing people with all types of cancer and their families. From 1997-1998, Ms. Stovall also served concurrently as Founder and President of THE MARCH…Coming Together To Conquer Cancer. Through her leadership, this national public awareness campaign focused both national and regional media attention on the issues of cancer research and quality care for all Americans. Ms. Stovall is co-chair of the Institute of Medicine's National Cancer Policy Board (NCPB), whose mandate is to confront obstacles and address public policy issues that arise in the prevention, control, diagnosis and treatment of cancer.

In 1996, Ms. Stovall was appointed by President Clinton to a six-year term on the National Cancer Advisory Board (NCAB), where she chairs the subcomittee on Planning and Budget. Ms. Stovall also chairs the Robert Wood Johnson Foundation's Committee to Promote Excellence in Care at the End of Life and serves on the National Advisory Board of the Robert Wood Johnson Foundation Program for Pursuing Perfection; Raising the Bar for Health Care Performance. In 1995, Ms. Stovall was made a member of the Board of Trustees of the Foundation for Accountability (FACCT). She also serves on advisory panels, working groups, and committees of the National Cancer Institute (NCI) and the American Society of Clinical Oncology (ASCO). Recognizing a need for the voice of cancer survivors to be heard during the national debate over health care reform, the Cancer Leadership Council (CLC) was convened in 1993 under her direction.

Today, Ms. Stovall is frequently called upon to work with Administration and Congressional staff on a variety of cancer-related policy issues, including access to quality care and cancer research funding.

ANNA D. BARKER, Ph.D.
President and CEO, BIO-NOVA
NCLAC Member

Dr. Barker has made ongoing efforts to accelerate the prevention and cure of cancer. She has a long history in both the performance and management of biomedical research, technology transfer, development, and product commercialization in the non-profit and private sectors. In 1998 she founded BIO-NOVA, Inc., which provides management, analytical and financial resources to support the discovery of new chemopreventives and therapeutics. The company facilitates the "translation" of innovative technologies into clinical development and focuses primarily on the discovery and development of novel agents to prevent cancer.

Dr. Barker has served in several capacities for the American Association for Cancer Research (AACR), including two terms as a member of the Board of Directors. She is a member of the AACR Public Science Policy and Legislative Affairs Committee, and has served as its Chairperson from 1993 until the present. Dr. Barker is also a member of the Boards of Directors of the National Coalition for Cancer Research (NCCR), the Ohio Cancer Research Associates (OCRA), the Oregon Medical Laser Center and the Oregon Biotechnology Association. She has been a member of the Integration panel (IP) of the Department of Defense's (DOD) Breast Cancer Research Program (BCRP) since 1993 and is immediate past Chairperson of the IP.

Among others, Dr. Barker has received the AACR Public Service Award, The Harriet H. Parker Award for Science and Technology, The Cancer Crusaders Award, and a named fellowship, the Anna D. Barker AACR Fellowship in Basic Science. She is an outspoken supporter and passionate advocate for a unified, reinvigorated and appropriately funded national "war" to conquer cancer. On October 10, 2001, as a co-author of the recently released National Cancer Legislative Advisory Committee (NCLAC) Report, Barker testified at the Hearing of the United States Senate Cancer Coalition. She regularly works with colleagues to develop and coordinate educational initiatives and response on national scientific policy and funding issues that affect cancer research, cancer patients and the national cancer program.